In This Section

Program

Please note that this meeting will take place as an in-person event in San Diego and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

Thursday, January 28

Friday, January 29

Saturday, January 30

SUNday, January 31

Thursday, January 28

Opening Keynote Lecture I

5:30-6:15 p.m.

  • 5:30 p.m. | Kevan Shokat, University of California, San Francisco, California

Rising Star Keynote Lecture

6:15-6:45 p.m.

  • 6:15 p.m. | Neeha Zaidi, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Poster Session A and Welcome Reception

7-9 p.m.

Friday, January 29

Plenary Session 1: RAS Signaling: RAS Isoforms, Effectors, and Activity Regulators

8-10 a.m.

  • 8 a.m. | Frank McCormick, University of California, San Francisco, San Francisco, California
  • 8:30 a.m. | Targeting RAS signaling for future therapy of NRAS-driven melanoma
    Martin McMahon, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
  • 9 a.m. How SHP2 activates RAS
    Benjamin Neel, NYU Langone Health, New York, New York

Short talks selected from proffered abstracts

Break

10-10:20 a.m.

Plenary Session 2: Preclinical and Clinical Advances in PDAC

10:20 a.m.-12:20 p.m.

  • 10:20 a.m. | Channing Der, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
  • 10:50 a.m. | Ignacio Garrido-Laguna, Moffitt Cancer Center, Tampa, Florida
  • 11:20 a.m. | Understanding RAS: It ain’t over ’til it’s over
    Dafna Bar-Sagi, Grossman School of Medicine, New York University, New York, New York

Short talks selected from proffered abstracts

Lunch Break

12:20-2 p.m.

Plenary Session 3: Preclinical and Clinical Advances in Lung Cancer

2-4 p.m.

  • 2 p.m. | KRAS mutant NSCLC: At the end of the beginning
    Melissa Johnson, Sarah Cannon Research Institute, Nashville, Tennessee
  • 2:30 p.m. | Chiara Ambrogio, Candiolo Cancer Institute, Candiolo, Italy
  • 3 p.m. | Kathryn Arbour, Memorial Sloan Kettering Cancer Center, New York, New York

Short talks selected from proffered abstracts

Break

4-4:20 p.m.

Plenary Session 4: Preclinical and Clinical Advances in Colorectal Cancer

4:20-6:20 p.m.

  • 4:20 p.m. | Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts
  • 4:50 p.m. | The landscape of RAS in CRC
    David Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:20 p.m. | Yijun Gao, Sun Yat-sen University Cancer Center, Guangzhou, China

Short talks selected from proffered abstracts

Poster Session B

6:30-8:30 p.m.

Saturday, January 30

Clinical Trials from Abstracts

8-10 a.m.

Break

10-10:20 a.m.

Plenary Session 5: Novel Therapeutic Approaches to Targeting the RAS Pathway

10:20-11:40 a.m.

  • 10:20 a.m. | Targeting RAS with Antibody-Drug Conjugates
    Raffaele Colombo, Zymeworks Inc., Vancouver, British Columbia, Canada
  • 10:30 a.m. | Jim Watters, Relay Therapeutics, Cambridge, Massachusetts
  • 10:50 a.m. | Matt Holderfield, Revolution Medicines, Redwood City, California

Short talks selected from proffered abstracts

Lunch

11:40 a.m- 1:20 p.m.

Plenary Session 6: RAS, Immunotherapy, Prevention, and Interception

1:20-3:20 p.m.

  • 1:20 p.m. | Targeting the interplay between oncogenic RAS signaling and tumor immune evasion in lung cancer
    Julian Downward, The Francis Crick Institute, London, England
  • 1:50 p.m. | Marina Pasca Di Magliano, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
  • 2:20 p.m. | Laura Wood, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2:50 p.m. | Anirban Maitra, NYU Langone, New York
  • 3:20 p.m. | RAS: Readiness and strategy
    Terri Conneran, KRAS Kickers, San Francisco, California

Short talks selected from proffered abstracts

Keynote Lecture

4-4:45 p.m.

  • 4 p.m. | Response and resistance to RAS inhibition in pancreatic cancer
    Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

Poster Session C

5-7 p.m.

Sunday, January 31

Plenary Session 7: Resistance Mechanisms and Combinatorial Approaches for RAS Targeting

8-10 a.m.

  • 8 a.m. | Sandra Misale, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 8:30 a.m. | Andrew Waters, University of Cincinnati, Cincinnati, Ohio
  • 9 a.m. | Elsa Quintana, Revolution Medicines, Redwood City, California
  • 9:30 a.m. | David Tuveson, Duke Cancer Institute, Durham, North Carolina

Short talks selected from proffered abstracts

Break

10-10:20 a.m.

Plenary Session 8: RAS Targeting in Hematological Malignancies

10:20 a.m.-12:20 p.m.

  • 10:20 a.m.  RAS pathway activation in AML therapeutic resistance
    Catherine C. Smith, University of California, San Francisco, California
  • 10:50 a.m. | Mrinal Patnaik, Mayo Clinic, Rochester, Minnesota
  • 11:20 a.m. | Targeting RAS is aggressive multiple myeloma
    Ryan M. Young, National Cancer Institute, Bethesda, Maryland—RAS targeting in multiple myeloma

Short talks selected from proffered abstracts

Closing Remarks

12:20 p.m.